Tag: Astellas Pharma

April 13, 2022 Off

EC Approves Astellas-Seagen’s Locally Advanced or Metastatic Urothelial Cancer Drug

Astellas Pharma Inc. and Seagen Inc. (Nasdaq:SGEN) have announced that the European Commission (EC) has approved PADCEV (enfortumab vedotin) as monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1/L1 inhibitor. The EC approval is supported by data from the global phase 3 EV-301 trial that demonstrated an overall survival (OS) benefit compared with chemotherapy.

March 29, 2021 Off

FDA approves new indication for Astellas Pharma’s bladder dysfunction drug

By Author

The U.S. Food and Drug Administration approved a new indication for Astellas Pharma’s Myrbetriq (mirabegron extended-release tablets) and Myrbetriq Granules (mirabegron for extended-release oral suspension) to treat neurogenic detrusor overactivity (NDO), a bladder dysfunction related to neurological impairment, in children ages three years and older.

April 28, 2020 Off

Harvard and Astellas team up in research alliance

By BusinessWire

Collaboration with Astellas supports advancement of Harvard biomedical research and Astellas drug discovery research in a range of therapeutic areas, Harvard said in a press release.

September 28, 2019 Off

Seattle Genetics, Astellas Phase 1 Trial of Investigational Agent Enfortumab Vedotin plus Pembrolizumab met outcomes: 71% patients confirm response.

By BusinessWire

Seattle Genetics, and Astellas Pharma’s study met outcomes for safety and 71 Percent of patients with locally advanced or metastatic urothelial (bladder) cancer had a confirmed response, the companies presented Saturday at ESMO Congress in Barcelona.

December 10, 2018 Off

Basilea pockets €8,84M from milestone sales of antifungal Cresemba in the US

By Dino Mustafić

The sale of antifungal Cresemba (isavuconazole) in the United States by Astellas Pharma, kicked off CHF 10 million (€8.84M) payment…

March 28, 2018 Off

Actinium to work with Astellas Pharma on its AWE Platform Technology

By Dino Mustafić

Actinium Pharmaceuticals and Astellas Pharma will work together to develop Actinium-225 Radio-Conjugates (ARCs) using Actinium Warhead Enabling (AWE) Platform Technology,…

June 9, 2017 Off

Astellas Pharma, Pfizer reduce target sample of patients in a cancer drug trial

By Dino Mustafić

Astellas Pharma and Pfizer have amended the protocol for the registrational PROSPER trial to test the efficacy and safety of Xtandi in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC).